Colleen Moore
Psychiatric/Mental Health · Spokane, WANPI 1720569593
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 276 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,399, more than ten times the $125 reported in 2022. Among psychiatric/mental health clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $27.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$869
- Lilly USA, LLC$594
- Eisai Inc.$534
- Merz Pharmaceuticals, LLC$446
- plus $3K from 21 others
What the payments were for
- Food & beverage$7,33497%
- Education$2433%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 53 | $1,175 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $1,112 |
| Teva Pharmaceuticals USA, Inc. | 36 | $869 |
| Lilly USA, LLC | 26 | $594 |
| Eisai Inc. | 19 | $534 |
| Merz Pharmaceuticals, LLC | 13 | $446 |
| Axsome Therapeutics, Inc. | 10 | $417 |
| Lundbeck LLC | 15 | $352 |
| Johnson & Johnson | 4 | $344 |
| Otsuka America Pharmaceutical, Inc. | 13 | $255 |
| Pfizer | 9 | $208 |
| Acadia Pharmaceuticals Inc | 8 | $200 |
| Ipsen Biopharmaceuticals, Inc | 8 | $196 |
| Neurocrine Biosciences, Inc. | 7 | $185 |
| Novo Nordisk | 2 | $161 |
| Biogen | 5 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $92 |
| Amneal Pharmaceuticals LLC | 3 | $84 |
| Vanda Pharmaceuticals Inc. | 2 | $47 |
| Alkermes, Inc. | 2 | $43 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| SK Life Science, Inc. | 1 | $22 |
| Revance Therapeutics, Inc. | 1 | $18 |
| Cala Health, Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Neuronetics, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,577 in reported general payments places this provider in the 95th percentile of 931 psychiatric/mental health providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 20 | $200,791 |
| Tetrabenazine | 14 | $94,707 |
| RexultiBrexpiprazole | 56 | $82,447 |
| CaplytaLumateperone Tosylate | 30 | $51,538 |
| SpravatoEsketamine Hcl | 39 | $49,455 |
| Lisdexamfetamine Dimesylate | 11 | $2,474 |
| Zolpidem Tartrate | 36 | $1,666 |
| Memantine Hcl | 94 | $1,421 |
| Duloxetine Hcl | 47 | $1,156 |
| Clomipramine Hcl | 11 | $1,107 |
| Aripiprazole | 40 | $1,090 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 13 | $830 |
| Bupropion XlBupropion Hcl | 38 | $810 |
| Mirtazapine | 22 | $724 |
| Hydroxyzine Hcl | 16 | $615 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $869 | $200,79120 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $255 | $82,44756 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,112 | $51,53830 claims |
| Johnson & JohnsonSpravato | $344 | $49,45539 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $84 | $17814 claims |
| Lilly USA, LLCOlanzapine | $594 | $15313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 931 psychiatric/mental health providers in Washington.
Other psychiatric/mental health in Spokane
- Dawn MasonSpokane$25K
- Favor OsakweSpokane$10K
- Nicholas GoodwinSpokane$5K
- Margaret KyakuwaSpokane$5K
- Kiira TietjenSpokane$5K
- Angela HamelSpokane$4K
- Angela CombsRichland$121K
- Ashley McGinnisAuburn$26K
- Courtney YantPuyallup$26K
- Jennifer WilsonYakima$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.